BETA

17 Amendments of Thomas ULMER related to 2010/2153(INI)

Amendment 11 #
Motion for a resolution
Recital A
A. whereas the national and international health authorities, including the WHO, were aware as early as May 2009 that the H1N1 influenza was not virulent, with this moderate virulence beinghaving since been confirmed by the very low mortality rate observed as a result of this influenza ‘pandemic’ in comparison with the officially recognised figures for seasonal influenza,
2010/12/20
Committee: ENVI
Amendment 19 #
Motion for a resolution
Recital B
B. whereas the criteria for defining a ‘pandemic’, as adopted by the WHO in 2009, andre based solely on the propagation of the virus while discounting the severity of the infection, distorted the meaning of the word ‘pandemic’ and triggered a false alarm worldwide, with that alarmism giving rise to inappropriate public health decisions and a disproportionate response among the public and administrations of the European Union and its Member States,
2010/12/20
Committee: ENVI
Amendment 32 #
Motion for a resolution
Recital C
C. whereas the exaggerated costs arising from the management of this crisis in the Member States are primarily a direct consequence of the EU’s lack of independence and critical acumen in relation to the risk evaluation concould perhaps have been reducted by the WHO,
2010/12/20
Committee: ENVI
Amendment 41 #
Motion for a resolution
Recital E
E. whereas this systematic vaccination strategy is based essentially on an approach that relies on blind faith in the effectiveness of influenza vaccines, without taking into account scientific data that contradict that belief (see Cochrane journals), and the majority of the studies available on the efficacy of the medicinal products, including vaccines, have been conducted by pharmaceutical companies, meaning that no objective proof has been provided of the efficacy of influenza vaccines,deleted
2010/12/20
Committee: ENVI
Amendment 53 #
Motion for a resolution
Recital F
F. whereas the differing recommendations made within the EU and the Member States on the subject of the priority groups targeted for vaccination illustrate the huge uncertainties surrounding the evaluation of the H1N1 vaccines recommenddiffered,
2010/12/20
Committee: ENVI
Amendment 54 #
Motion for a resolution
Recital F a (new)
Fa. whereas assessments of the vaccines differed,
2010/12/20
Committee: ENVI
Amendment 58 #
Motion for a resolution
Recital G
G. whereas significant changes are required to the current healthcare system in the EU and its Member States in order to achieve general public health objectives, as opposed to a purely pharmacological approach,deleted
2010/12/20
Committee: ENVI
Amendment 61 #
Motion for a resolution
Recital I
I. whereas confidence in vaccines against H1N1 influenza was also undermined by the partial transfer from the manufacturer to the Member State, in the purchase contracts, of liability for any side effects,deleted
2010/12/20
Committee: ENVI
Amendment 71 #
Motion for a resolution
Recital J
J. whereas information has been garnered by various parliamentary committees and evaluation missions conductedby means of evaluation measures carried out in the EU Member States on the action taken to combat H1N1 influenza,
2010/12/20
Committee: ENVI
Amendment 78 #
Motion for a resolution
Paragraph 1
1. Calls for the prevention plans established in the EU and its Member States to be revised to make them sufficiently autonomous and flexible toflexible so that they can be adapted as swiftly as possible and on a case by case basis to the actual risk, based not least on the latest scientific information available;
2010/12/20
Committee: ENVI
Amendment 93 #
Motion for a resolution
Paragraph 2
2. Takes the view that the powers of the European Centre for Disease Prevention and Control (ECDC) should be reinforced so that the EU has its own means of assessing the severity of infection risk, by establishing, if necessary, its own health alert scale independent of inter cooperation with national organisations such as the WHO;
2010/12/20
Committee: ENVI
Amendment 96 #
Motion for a resolution
Paragraph 3
3. Demands that robust, credible and effective scientific procedures be introduced for the evaluation of medicinal products recommended in the event of health emergencies, and more particularly in genuine pandemic situations;deleted
2010/12/20
Committee: ENVI
Amendment 107 #
Motion for a resolution
Paragraph 4
4. Calls for immediate clarifications on the effectiveness of the influenza vaccination strategies recommended in the EU, given the weight of evidence casting doubt on their effectiveness, the absence of reliable data guaranteeing that effectiveness and the lingering uncertainties surrounding their benefit-risk profile;
2010/12/20
Committee: ENVI
Amendment 129 #
Motion for a resolution
Paragraph 8
8. Considers the conflicts of interest apparent in the case of some experts who advise the European institutions to give rise to suspicions of undue influence and to undermine the overall credibility of the European health agencies and their recommendations; calls in particular for the EMA and ECDC to revise forthwith their current and future expert screening procedures to ensure complete transparency;deleted
2010/12/20
Committee: ENVI
Amendment 138 #
Motion for a resolution
Paragraph 9
9. Calls for the publication of the names, roles and potential conflicts of interest of senior officials who are members of informal groups such as the EU’s Health Security Committee, the Health Emergency Operational Facility (HEOF) and the ‘vaccines’ task force;deleted
2010/12/20
Committee: ENVI
Amendment 159 #
Motion for a resolution
Paragraph 11
11. Demands precise definition of the roles, duties, remits, limits, relations and responsibilities of the Commission, the ECDC, the EMA and the Member States and also of more informal entities such as the Health Security Committee, the HEOF and the ‘public health’ group, composed of senior officials able to intervene in the decision-making process regarding the management of a health crisis;
2010/12/20
Committee: ENVI
Amendment 165 #
Motion for a resolution
Paragraph 12
12. Expresses its approval of the introduction of a procedure enabling the Member States to make group purchases of anti-viral vaccines and medicinal products on a voluntary basis where the positive benefit-risk profile of their preventive/therapeutic effect is clearly demonstrated and indisputable, in order to obtain, for a given product, advantageous rates approaching its cost price;
2010/12/20
Committee: ENVI